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ABSTRACT 
 
The Bcl-2 family of proteins contains both anti-apoptotic (e.g.Bcl-2, Bcl-xL) and pro-
apoptotic (e.g.Bad, Bcl-xS) proteins. Bcl-xL and Bcl-xS are splice variants, but have different 
functions during apoptosis. The pro-survival kinase Akt can phosphorylate certain Bcl-2-
related proteins, specifically on serine residues, to regulate their function and localization. 
This is an extension of the work from our laboratory’s finding that haloperidol promotes 
PC12 cell death by inducing Bcl-xS which then translocates from cytosol to mitochondria and 
facilitates the release of cytochrome c. The toxicity induced by Bcl-xS is reversed by 
expression of constitutively active Akt. I hypothesized that Akt-mediated post-translational 
modification may be important for regulating the function of Bcl-xS as well as Bcl-xL. 
 Three specific serine residues were ultimately chosen for the characterization of Bcl-
xS/xL function: Serine62 (homologous to Serine70, a major site for phosphoregulation, in 
Bcl-2), Serine106 (putative Akt phosphorylation motif), and Serine165 in Bcl-xS (and the 
corresponding Serine228 in Bcl-xL) (immediately upstream of hydrophobic tail). The 
individual substitutions of all three Serines with Alanines (Ser/Ala; S/A: which precludes 
phosphorylation at that site) in Bcl-xS did not affect the expression of the protein, but they did 
induce varying degrees of cytotoxicity in both PC12 and HEK cultures. I focused on the 
Ser106 substitution mutant given my hypothesis that Akt targeted this site. Overexpression of 
Bcl-xS(S106A) was toxic in both PC12 and HEK cultures, as expected, and this coincided 
with the appearance of the Bcl-xS(S106A) protein in the mitochondrial fraction. The release 
of cytochrome c from PC12 cell mitochondria coincided with the co-immunoprecipitation of 
the Bcl-xS protein with VDAC (voltage-dependent anion channel), a channel-forming protein 
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that is known to mediate cytochrome c release, and with the initiation of caspase-dependent 
events. This was not the case in HEK cells, where the mitochondrial VDAC seemed to be 
diminished and the toxicity was cytochrome c-independent as well as caspase-independent. In 
addition, I was able to demonstrate that Bcl-xS(S106A) did not co-immunoprecipitate with 
Akt, supporting Ser106 as a potential target for the Akt protein. I then studied the effects of 
the homologous substitutions in Bcl-xL on cell function. I chose to use treatment with the 
potent inducer of apoptosis, staurosporine, as a model of cytotoxicity. Again, substituted 
proteins exerted toxicity, but they did not potentiate the effects of staurosporine, at least not 
on MTT conversion. I did notice, however, that there was a clear morphological change with 
certain concentrations of staurosporine, and subsequently demonstrated that the Bcl-
xL(S106A) protein potentiated PC12 cell differentiation induced by staurosporine. The Bcl-
xL(S106A)  protein also co-immunoprecipitated better with Akt, which was unexpected given 
my results with the Bcl-xS(S106A) protein described above. Perhaps the extra amino acids in 
Bcl-xL account for this. 
 It is clear that the phosphorylation of Bcl-xS and Bcl-xL proteins is an important 
means of regulating their function and localization within the cell. These data support the 
Ser106 residues in both Bcl-xS and Bcl-xL as novel targets for the pro-survival Akt kinase, 
and indicate a role for this/these residue(s) in cellular functions as diverse as apoptosis and 
differentiation. 
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1. Introduction 
1.1 Apoptosis  
 Apoptosis is a mechanism of cell ‘suicide’ designed to maintain homeostasis and 
often is associated with programmed cell death. The actual mechanism involves a series of 
biochemical events leading to a characteristic change in cell morphology that includes 
chromatin aggregation, nuclear and cytoplasmic condensation, nuclear fragmentation, release 
of cytochrome c from the mitochondria to the cytosol and, ultimately, the shrinkage of the cell 
and its breakup into pieces called apoptotic bodies. There are two main apoptotic pathways, 
termed the intrinsic and extrinsic pathways (Fig. 1.1) [1-4]. Occasionally, these two pathways 
cross-talk and form an amplified feedback loop [1, 4]. 
Aspartic acid-specific cysteine proteases (also known as cysteine aspartate-specific 
proteases or caspases) are a family of enzymes that are essential for intrinsic as well as 
extrinsic apoptotic pathways. There are two types of caspases that are generally characterized 
according to differences in structure and function. ‘Initiator caspases’ include caspase-2, -8, -9, 
and -10, and activate apoptotic processes by cleaving (and, thus, activating) the pro-forms 
(inactive) of effector caspases. ‘Effector caspases’ (also called ‘executioner caspases’) include 
caspase-3, -6, and -7, all of which cleave other proteins that trigger the irreversible (hence 
‘executioner’) aspects of the apoptotic process [1, 2]. Caspase-8 is a mediator of the extrinsic 
pathway whereas caspase-9 mediates the intrinsic pathway.  
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Figure 1.1: The extrinsic and intrinsic apoptotic signaling pathways. The two pathways 
mediating cell apoptosis are called the extrinsic apoptotic pathway, also known as death-
receptor mediated pathway (pathway on the left), and the intrinsic apoptotic pathway, also 
known as mitochondria pathway (pathway on the right). In Caspase-dependent apoptosis, 
caspase-8 is an example of a regulator of the extrinsic apoptotic pathway whereas caspase-9 is 
an example of a regulator of the intrinsic apoptotic pathway. Those two pathways can cross-
talk to amplify the apoptotic signal. (Adapted from Ref [1])  
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1.1.1 The extrinsic apoptotic pathway  
The extrinsic apoptotic pathway is also known as the death-receptor regulated pathway. 
When a death ligand, such as FasL (Fas ligand) or TNF (tumor necrosis factor), binds to its 
corresponding receptor (e.g. Fas or TNF receptor, respectively), it recruits the pro-form of 
initiator caspases that are cleaved and then dimerized. Once activated, they, in turn, activate 
the effector caspase (Fig. 1.1). The activated effector caspase targets several substrates such as 
the transcription factor (NF-kB) or the enzyme poly(ADP-ribose) polymerase (PARP: 
required for efficient DNA repair of single-strand breaks) [5], either of which promotes an 
apoptotic phenotype. 
 Fas is a type I transmembrane receptor protein and FasL is a type II transmembrane 
protein. Fas can mediate apoptosis by ligation with FasL; a Fas trimer binds to the Fas-
associated death domain (FADD) protein which acts as a bridge between death receptors and 
caspases. Oligomerization of FADD binds pro-caspase-8 and forms the death-inducing-
signal-complex (DISC). Caspase-8 then dimerizes and dissociates from DISC, and then is 
freed to activate the effector caspase-3 in the cytosol [4, 6]. 
 TNF binds TNFR to initiate another cascade. For example, TNF-α binds TNFR I, 
and TNFR I is trimerized and recruits an adaptor protein called TNFR-associated death 
domain (TRADD). TRADD can then bind with FADD to form a dimer. This then activates, as 
described above, pro-caspase-8 and initiates apoptosis [6].  
 
1.1.2 The intrinsic apoptotic pathway  
 The intrinsic apoptotic pathway is also known as the mitochondrial apoptotic 
pathway given the crucial role of mitochondrial outer membrane permeabilization (MOMP) in 
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this pathway [7]. The regulation of MOMP depends, in large part, on modulation by the 
function of the voltage-dependent anion channel (VDAC). When a cell is affected by stressors 
such as radiation, reactive oxygen species (ROS) or chemotherapeutic reagents, the 
mitochondria can respond, because of a change in VDAC function and MOMP, by releasing 
cytochrome c to the cytosol. Cytosolic cytochrome c binds the apoptotic-protease-activating-
factor 1 (APAF1) and pro-caspase-9 to form the apoptosome. The apoptosome activates the 
effector caspase-3 and eventually leads to apoptosis [2-4]. In addition, a second 
mitochondrial-derived activator of caspase can be released from mitochondria and blocks the 
inhibitor-of-apoptotic proteins and exacerbates the apoptotic signal.  
 These apoptotic cascades are tightly regulated, for obvious reasons. Proteins such as 
those belonging to the Bcl-2 family of proteins can influence a cell’s response to a stressor by 
either promoting or inhibiting the apoptotic process. This can be done, for example, by 
regulating MOMP or by regulating cytochrome c function [8]. 
 
1.2 The Bcl-2 family of anti- and pro-apoptotic proteins 
 The B-cell lymphoma 2 (Bcl-2) family of proteins comprises both anti-apoptotic (e.g. 
Bcl-2, Bcl-xL, Mcl-1) and pro-apoptotic (e.g. Bad, Bax, Bcl-xS) members, and plays a 
prominent role in regulating apoptosis. Bcl-2 family members are able to promote or inhibit 
apoptosis directly by regulating MOMP or indirectly by regulating the function(s) of other 
protein(s). Bcl-2-related proteins contain Bcl-2 homology (BH) domains that allow them to 
form homo- or heterodimers that ultimately define their anti- or pro-apoptotic functions. 
Recent studies reveal that the phosphorylation of Bcl-2 family proteins is important in 
regulating their function during apoptosis. The following is a brief discussion of Bcl-2-related 
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proteins as well as the various mechanisms known to regulate their influence on cell viability. 
 
1.2.1 Anti-apoptotic and pro-apoptotic Bcl-2-related proteins 
 Bcl-2, Bcl-xL, Bcl-W, Bcl-2A1, MCL1, and BOO are anti-apoptotic members of 
Bcl-2 family; Bax, BOK, Bcl-xS, Bak, Bad, BIK, BID, HRK and BIM are all examples of 
pro-apoptotic members of the same family [3]. Bcl-2 was discovered in the 1980s as a proto-
oncogene. Overexpression of Bcl-2 could protect against neuronal cell death by arresting cell 
cycle at the G1 stage [9, 10]. The various Bcl-2 homology (BH) domains in this protein allow 
for the formation of heterodimers with pro-apoptotic Bcl-2-related proteins (and thereby 
sequestering them and arresting apoptosis). 
 
1.2.2 The BH domain of Bcl-2 family-related proteins  
 The Bcl-2 family of proteins is characterized by the presence of specific regions of 
homology, the aforementioned Bcl-2 homology (BH1, BH2, BH3 and BH4) domains (Fig. 
1.2). BH domains are critical to the function of Bcl-2 family proteins and alter their impact on 
cell survival and their ability to interact with other family members and regulatory proteins [3, 
11]. BH domains allow Bcl-2 family members to interact and form homo- or heterodimers. 
 Bcl-2 family proteins contain both anti- and pro- apoptotic protein members. The 
anti-apoptotic members all have four BH domains (the exception being MCL1, which only 
has BH1 and BH3 domains). The flexible loop structure between BH3 and BH4 domains in 
Bcl-2 and Bcl-xL is believed to be a regulatory region for their function [12]. The pro-
apoptotic protein members can be divided into two subgroups: (i) the Bax/Bak-like proteins 
and (ii) the BH3-only proteins. The Bax/Bak-like proteins contain at least two BH domains, 
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Figure 1.2: BH domains in Bcl-2 family proteins. Bcl-2 family contains both anti- and pro- 
apoptotic protein members. All anti-apoptotic members contain the four BH domains, except 
MCL1 which only has BH1 and BH3 domains. The pro-apoptotic members can be divided 
into two subgroups: (i) the Bax/Bak-like proteins which contain at least two BH domains, and 
(ii) the BH3-only proteins. TM: transmembrane domain, allows Bcl-2 family members to 
target membranes. (Used with permission; Ref [3])  
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whereas the BH3-only protein members, as their name implies, only contain a BH3 domain 
(Fig. 1.2). The BH3 domain has high affinity for, and inactivates, anti-apoptotic proteins [3], 
yet the BH3-only protein, BID, does not interact with anti-apoptotic Bcl-2 members, but is 
actually cleaved by caspase-8 and mediates Fas/FasL-mediated apoptosis [13, 14]. The 
transmembrane domain (TM) allows Bcl-2 family member to target intracellular membranes, 
such as the outer membrane of the mitochondria. 
 
1.2.3 Examples of Bcl-2-related proteins 
 MCL1 (myeloid-cell leukemia sequence 1) promotes cell viability and interrupts 
apoptotic signal by binding with pro-apoptotic members (e.g. BIM). MCL1 has a very short 
half-life [15] and its function is regulated at the post-translational level. MCL1 is a target for 
proteasome degradation and the process is phosphorylation-dependent [16, 17]. BOO (Bcl-2 
homologue of ovary, also known as DIVA) is a newly discovered regulator of apoptosis that 
contains four BH domains unlike MCL1, which only has two. BOO inhibits the binding of 
Bcl-xL with APAF1 [18], but there is lack of evidence in support of its anti-apoptotic activity.  
 Two classes of proteins comprise the pro-apoptotic members of the Bcl-2 family. 
One is Bax/Bak-like protein which includes Bax, BOK, Bcl-xS and Bak, whereas the other 
includes the BH3-only proteins Bad, BIK, BID, HRK and BIM [3]. The following is a cursory 
description of each protein. 
 Although Bax (Bcl-2 associated X protein) and Bak (Bcl-2 antagonist killer) are 
structurally similar to the anti-apoptotic Bcl-xL, and are normally sequestered and inactivated 
by heterodimerization with Bcl-xL within the cytosol, they are actually pro-apoptotic and 
function by translocating from the cytosol to the mitochondria where they regulate the 
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opening of the permeability transition pore complex [19]. This allows for cytochrome c 
release to the cytosol and caspase activation. The effects of BOK (Bcl-2 related ovarian killer) 
are not antagonized by anti-apoptotic Bcl-2-related proteins such as Bcl-2 or Bcl-xL and 
appear to depend on its ability to localize to the nucleus (by virtue of a Leucine-rich sequence 
within its BH3 domain) [20]. 
 BH3-only proteins include Bad (Bcl-2 antagonist of cell death), which transduces 
the death signal to the mitochondria by interfering with the association between Bcl-xL and 
Bax. This not only allows Bax to translocate to the mitochondria and affect VDAC function, 
but it also diminishes the ability of Bcl-xL to bind with APAF1 or other pro-apoptotic 
proteins [21]. BIK (Bcl-2 interacting killer) can bind with various anti-apoptotic proteins 
through its BH3 domain, but the heterodimer alone is not sufficient to induce apoptosis; it is 
believed that phosphorylation of BIK may promote its toxicity [22]. HRK (hara-kiri, also 
known as DP5) is regulated by the transcription factor pRB [23] and mediates apoptosis 
related with growth factor withdrawal [24]. BIM (Bcl-2 interacting mediator of cell death) 
promotes apoptosis by binding with LC8 cytosol dynein light chain and Bcl-2. This releases, 
and activates, Bax [25, 26]. BID (BH3 interacting domain death agonist) is very important in 
Fas-mediated apoptosis since BID is cleaved by caspase-8 and the truncated BID (tBID) 
translocates from cytosol to mitochondria and triggers the release of cytochrome c (Fig.1.1a). 
 
1.2.4 Phosphorylation on Bcl-2-related proteins 
It is known that structural features such as BH domains dictate the inherent function of 
Bcl-2-related proteins. However, clinical data based on small cell lung carcinoma [27] or 
breast cancer cells [28] have revealed that increased expression of Bcl-2 is itself not sufficient 
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to suppress drug-induced apoptosis and chemoresistance. These findings suggest that 
additional factors, such as post-translational modification, e.g. phosphorylation, could also 
regulate its function [29, 30]. Phosphorylation of some Bcl-2 family members, especially on 
serine residues, can influence their anti- or pro-apoptotic function.  
For example, Bcl-2 can be phosphorylated at the flexible loop domain on Ser70 by 
interleukin-3 or protein kinase C to support prolonged cell survival [12, 31]. It can also be 
phosphorylated on Thr56 site by JNK (a subgroup of mitogen activated kinases) during 
mitosis [32]. JNK can also phosphorylate Bcl-2 on additional Serines [33, 34] and either 
activate or inhibit its anti-apoptotic function. 
Bcl-xL is phosphorylated at the activation loop on Ser62 (homologous to Ser70 on 
Bcl-2, above) by JNK, which not only modulates the Bax/Bcl-xL interactions [35], but also 
inhibits Bcl-xL function [36]. Phosphorylation on Thr47 and Thr115 by SAPK/JNK (stress 
activated protein kinase) also promotes apoptosis, and, not surprisingly, overexpression of 
Bcl-xL bearing substitution of these Serines with Alanines (thus precluding phosphorylation 
on these sites) promotes cell survival during under stress [37]. 
 Phosphorylation on MCL1Ser64 by CDK during G2/M phase enhances the binding 
of MCL1 with BIM and Bak to inhibit apoptosis [15], and phosphorylation on Thr163 can 
prolong it’s half-life [16]. BIM is phosphorylated on Ser87 by Akt, which may diminish its 
apoptotic function by increasing its binding with the cytoplasmic 14-3-3 proteins (which 
would sequester it) [26]. Bax is also phosphorylated by Akt on Ser184, which retains Bax in 
the cytosol and inhibits its ability to translocate to the mitochondria and initiate the 
mitochondrial apoptotic pathway [38]. In contrast, phosphorylation of Bax on Ser163 by 
GSK-3β promotes its translocation to the mitochondria and the induction of apoptosis [39]. 
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BID is phosphorylated by casein kinase I and II on Ser61, Ser64 and Ser78 residues, all of 
which, when phosphorylated, attenuate caspase-8-mediated BID cleavage, thereby blocking 
Fas-mediated apoptosis [13, 14]. Bad displays pro-apoptotic activity when heterodimerized 
with Bcl-2 or Bcl-xL, and can be phosphorylated at multiple sites, e.g. on Ser112 by ERK and 
on Ser136 by Akt [40], which promotes its binding with the cytoplasmic 14-3-3 protein. The 
binding of Bad with 14-3-3 impedes its ability to disrupt the Bax:Bcl-2 (or Bax:Bcl-xL) 
heterodimers and promotes cell survival. Phosphorylation of Bad on Ser136 also permits 
subsequent phosphorylation on Ser155 by protein kinase A [41]. Finally, phosphorylation of 
Bad on Ser170 [42] is also important for promoting cell survival.  
 
1.2.5 Bcl-xS and Bcl-xL 
 Pro-apoptotic Bcl-xS and anti-apoptotic Bcl-xL are derived from the same gene, but 
are splice variants: xS represents the short form of the gene/protein, whereas xL represents the 
long form of the gene/protein (Fig.1.3). The Bcl-xL gene encodes 233 amino acids and 
contains all four BH domains, whereas the shorter Bcl-xS gene encodes 170 amino acids and 
only contains the BH3 and BH4 domains near its transmembrane domain (TM). 
  The pro-apoptotic protein Bcl-xS is normally expressed at very low levels and is 
primarily cytosolic. However, when it is overexpressed, Bcl-xS causes caspase activation and 
apoptosis [43] as a result of its ability to translocate to the mitochondria where it interacts 
with VDAC and facilitates cytochrome c release to the cytosol [19, 44-46]. Its apoptotic 
function is inhibited by co-overexpression of Bcl-xL. 
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Figure 1.3: Amino acid sequences of Bcl-xL and Bcl-xS. (top) Schematic of the presence 
and distribution of BH domains in Bcl-xL and Bcl-xS. (bottom) The deduced amino acid 
sequences for Bcl-xL and Bcl-xS are aligned and show great sequence identity, which is not 
unexpected as they are splice variants. Specific Serine residues (shown in red) were ultimately 
chosen for the characterization of Bcl-xS/xL function. Ser62 (inactivation mutant, based on 
homology to Ser70 in Bcl-2), Ser106 (putative Akt phosphorylation motif), and Ser165 in 
Bcl-xS or Ser228 in Bcl-xL (immediately upstream of hydrophobic tail and homologous to 
Ser184 in Bax); the dotted line represents the amino acids missing due to an exon deletion 
from the Bcl-xL gene, making the overall gene/protein shorter, e.g. Bcl-xS (“S” for short). 
BH1, BH2, BH3 and BH4: Bcl-2 homology domains. 
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 The anti-apoptotic protein Bcl-xL normally localizes to the outer membrane of 
mitochondria where it regulates VDAC function and blocks caspase activation and cell death .  
 
1.3 The voltage-dependent anion channel (VDAC)  
 Mitochondria play a crucial role in regulating the intrinsic apoptotic pathway. In this 
pathway, caspase activation is closely related to MOMP [7], which depends on the function of 
the permeability transition pore complex [47].  
 The permeability transition pore complex consists of a VDAC-ANT (adenine 
nucleotide translocator) complex and other proteins such as peripheral benzodiazepine 
receptor, Hexokinase II, and cyclophilin D [47, 48]. VDAC is expressed on the outer 
mitochondrial membrane, where it interacts with several cytosolic proteins and mitochondrial 
proteins such as Bcl-2 family members which regulate (block or promote) the release of 
cytochrome c to cytosol [19, 44, 49-51]. The ANT is expressed on the inner membrane of 
mitochondria and allows the exchange of ADP and ATP at the inner membrane.  
 When a cell receives a stress signal such as increased oxidative stress or a high level 
of Ca2+, the result can be the decrease in mitochondrial membrane potential. This causes 
disruption of the VDAC-ANT pore complex (which normally connects the inner and outer 
mitochondria membrane to allow for ATP transfer from the inside of the mitochondria to the 
cytosol). The disrupted pore complex now allows the “leaking” of cytochrome c from the 
intramembrane space into the cytosol where it activates the caspase cascade, eventually 
leading to DNA damage and apoptosis. Pro-apoptotic Bcl-2 family members, such as Bax and 
Bak, can facilitate the pore dysfunction by interacting with VDAC, but the action is inhibited 
by the anti-apoptotic proteins Bcl-2 and Bcl-xL . The BH1 and BH4 domains of Bcl-2 and 
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Bcl-xL play an important role in maintaining pore closure [46]. Interestingly, the function and 
interaction of Bcl-2-related proteins such as Bcl-xS and Bcl-xL with VDAC is, in part, 
regulated by Serine phosphorylation downstream of the PI3K/Akt signaling pathway [44, 52, 
53]. 
 
1.4 The PI3K/Akt pathway  
 The phosphatidylinositol-3'-kinase (PI3K)/Akt pathway is involved in functions as 
diverse as cell survival, proliferation and differentiation [54, 55]. Recent studies also suggest 
that PI3K/Akt pathway is involved in human tumor formation and angiogenesis, making it a 
suitable candidate for therapeutic treatment [56, 57].  
Akt, also known as protein kinase B, is a Serine/Threonine kinase and the downstream 
target of PI3K. It is now acknowledged that Akt is activated directly by the Serine/Threonine 
kinase 3'-phosphatidylinositol dependent kinase-1 (PDK1) and that Akt function is limited by 
the protein and lipid phosphatase PTEN (phosphatase and tensin homologue deleted on 
chromosome 10). 
PI3K, a plasma membrane-associated kinase that often interacts with receptor 
Tyrosine kinases (e.g. growth factor receptors), contains two subunits: the p85 regulatory 
subunit and p110 catalytic subunit. The p85 subunit relocalizes PI3K from the cytosol to the 
plasma membrane. At the membrane, the p110 catalytic subunit phosphorylates 
phosphatidylinositol at the 3' position of the hydroxyl group and generates lipid product such 
as PI3,4,5P3 and PI3,4P2. These lipid products recruit PDK1 to the membrane where it gets 
phosphorylated, thus activating it. These same lipid products also recruit Akt to the membrane. 
The proximity to PDK1 allows the latter to phosphorylate Akt on Thr308, which facilitates 
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the subsequent phosphorylation of Akt on Ser473 [58, 59]. Only once both Thr308 and 
Ser473 of Akt are phosphorylated is Akt fully activated and able to target a pool of substrates 
including GSK-3β (important for cell cycle entry) [60], S6K (important for protein translation) 
[61, 62], and also Bax, Bad, BIM, and Bcl-xL [44, 53, 59, 63, 64]. 
 Some psychiatric medications such as antipsychotics and antidepressants also affect 
PI3K/Akt function. Sertraline (antidepressant; 5-HT uptake inhibitor) kills melanoma cells by 
inhibiting Akt phosphorylation [65], whereas antipsychotics such as phenothiazines or 
haloperidol (at higher dose) inhibit the Akt pathway in human ovary cancer cells [66] and in 
PC12 cells [67], respectively. This ability to kill cells via inhibition of Akt, while not helpful 
in treating mental disorders, could be useful in cancer treatment, where apoptosis is desirable. 
 
1.5 Chemical reagents that lead to apoptosis 
Haloperidol (HAL) is a typical antipsychotic used in the treatment of schizophrenia, 
but its adverse effects, including cognitive deficit, were higher than those associated with 
other antipsychotic drugs [68-71]. Patients are currently prescribed other antipsychotic drugs 
which present less adverse effects. Due to its toxicity, HAL is not approved for behavioral 
treatment of the elderly, particularly those with dementia, yet HAL, because of its low cost, 
remains one of the most commonly prescribed antipsychotic drugs worldwide to treat patients 
with positive symptoms of schizophrenia [72]. Higher doses of HAL (50-100 μΜ) are 
routinely used in experimental settings because of their ability to induce cytotoxicity and, 
particularly, apoptosis [69, 70].   
Staurosporine is a potent phospholipid/Ca2+-dependent kinase inhibitor [73, 74]. It 
induces apoptotic cell death by activating caspase-3 in neural stem cells [75] and osteoblasts 
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[76], and inhibits Akt [77], thus making it a potential cancer therapeutic [74]. While 
staurosporine is used regularly to study cytotoxicity in vitro [78-81] and to study nuclear 
condensation (a marker for apoptosis) and cell cycle arrest at G1/S phase [82], it also induces 
neurite outgrowth (a sign of differentiation) in PC12 cells [83, 84]. 
 
1.6 Pheochromocytoma PC12 cells 
  PC12 cells are derived from a pheochromocytoma and under normal conditions they 
develop properties similar to immature rat adrenal chromaffin cells. When grown in the 
presence of nerve growth factor, PC12 cells exhibit neurite outgrowth, become electrically 
excitable, are more responsive to exogenous acetylcholine and synthesize more 
neurotransmitters, particularly noradrenaline [85, 86]. There are mainly two cascades that 
contribute to the apoptosis in PC12 cells. One is Bax-dependent and caspase-independent 
cascade, whereas the other is Bcl-xS- and caspase/mitochondrial-dependent [43, 44, 87]. Thus, 
PC12 cells represent a good in vitro model for examining the influence of the respective 
cascades in drug-induced apoptosis. 
 
1.7 Summary of the thesis project 
 The Bcl-xL and Bcl-xS proteins are splice variants, but exert different functions 
during apoptosis. In previous studies from our laboratory, we found that haloperidol induces 
PC12 cell death by inducing (gene and protein) Bcl-xS, which translocates from the cytosol to 
the mitochondria and facilitates the release of cytochrome c. This translocation of Bcl-xS 
appears to be regulated by the [de]phosphorylation of specific Serine residues. Furthermore, 
Bcl-xS-induced toxicity is reversed by constitutively active Akt [44]. These combined data 
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suggest an Akt-sensitive post-translational modification of the Bcl-xS protein that determines 
its localization and toxicity profile. Interestingly, Bcl-xL function is also regulated, in part, by 
the Serine phosphorylation downstream of the PI3K/Akt survival signaling pathway [52, 53].  
 Based on these observations, I hypothesized that the activity of Bcl-xL in PC12 cells 
is regulated by the phosphorylation of specific Serine residues and that this could alter its 
ability to protect against specific chemical inducers of apoptosis. I chose to compare and 
contrast the effects of Bcl-xL to those of Bcl-xS. 
 I chose to target three specific Serine residues in Bcl-xL, e.g. Ser62, Ser106 and 
Ser228 (homologous to Ser165 in Bcl-xS) (shown in Fig.1.3) for mutagenesis. Therefore, 
these were substituted to Alanines which precludes phosphorylation on these sites. This was 
done so as to examine: 
1. If the substituted Bcl-xS and Bcl-xL variants affect the viability of PC12 pre-neuronal 
cells and/or HEK293 non-neuronal cells;  
2. If so, do the variants exert an effect that is different from the parental wildtype protein; 
3. If the substitutions affect the proteins’ ability to interact with other proteins under 
conditions of cell stress, e.g. during treatment with staurosporine; 
4. Whether mutagenesis of Ser106, which resides within a putative Akt consensus motif, 
affects the proteins’ ability to respond to the PI3K/Akt pathway.  
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2. Materials and Methods 
2.1 Materials 
 All materials and reagents used in this series of experiments were obtained from 
commercial sources (company indicated in brackets after the reagent). The name and 
company address are listed in Table 2.1. 
 
2.1.1 Cell lines 
 The rat pheochromocytoma (PC12, ATCC, CRL-1721), human embryonic kidney 
293A cell (HEK293A, ATCC, CRL-1573) and rat primary cortical cultures were used during 
these experiments. PC12 cells are pre-neuronal cells and can exhibit neurite outgrowth upon 
differentiation. HEK293A cells are non-neuronal cells and have a high capacity for protein 
overexpression. 
 
2.1.2 Vectors  
 The expression vector pcDNA3.1 (+) (Invitrogen) is used for high level of protein 
overexpression in mammalian cells. pCMV/FLAG3 was kindly provided by Dr. Deborah 
Anderson (Saskatchewan Cancer Center, University of Saskatchewan) and is used for 
overexpression and isolation of FLAG-tagged proteins. Both vectors carry the ampicillin 
resistance gene (Amp+). 
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2.1.3 Plasmids  
 Bcl-xL wildtype (WT) cDNA was amplified from the pcDNA3-Bcl-xL plasmid 
(Richard Youle, NINDS, NIH) and subcloned into pCMV/FLAG3. pCMV/FLG3-Bcl-xL was 
then used to generate the S62A, S106A and S228A substitutions using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene).  
 
2.1.4 Competent cells  
 The DH5α E. coli bacterial strain was used to make competent cells (used for 
transforming with plasmid cDNA, see Section 2.2.3, below) and was obtained from ATCC. 
 
2.1.5 Antibodies  
 The antibodies used in this thesis are indicated below in Table 2.2. Primary 
antibodies were diluted by using 5% BSA (EMD Chemicals Inc.) in TBS-Tween 20, 
incubated at 4 ºC for overnight. Secondary antibodies were diluted in 5% milk in TBS-Tween 
20. All antibodies are either stored in 4ºC or -20ºC according to the manufacturer’s 
specifications. 
 
2.2 Methods 
2.2.1 Cell culture 
 PC12 cells were incubated at 37ºC in Ham’s F-12 Kaighn’s Modification (Hyclone) 
nutrient medium supplemented with 15% horse serum and 2.5% fetal bovine serum in an 
atmosphere with an additional 5% CO2. Culture plates and flasks for PC12 cells were pre-
coated with rat-tail collagen (BD Bioscience). 
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HEK293A cells were incubated at 37ºC in 5% CO2 and maintained in low glucose 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum. 
 Rat primary cultures were prepared from time-pregnant (i.e. the date of conception is 
known) Sprague-Dawley rats [88]. E20 fetuses were anesthetized and decapitated. The brains 
were dissected and the cortical area was removed into Hank’s Balanced Salt Solution (HBSS, 
GIBCO) supplemented with 15 mM HEPES and 30U/ml penicillin/streptomycin (all from 
GIBCO). The cortical tissue was digested at 37ºC with Trypsin-EDTA (Sigma) for 15 min. 
An equal volume of FBS was added to stop digestion, and the tissue was then rinsed in HBSS 
three times to remove any FBS. The tissue was then disrupted with several aspirations into a 
glass Pasteur pipette. HBSS was then added to a final volume of 5 ml. After centrifugation, 
the HBSS was removed and the cells were re-suspended in NeuroBasal medium with 1% N2, 
2% B27, 25 μM L-glutamate, and 20U/ml penicillin/streptomycin. Neuronal cells were plated 
into 96-well plates pre-coated with 25 μg/ml Poly-D-Lysine in a density of 8×104/well and 
incubated at 37ºC with 5% CO2-humidified atmosphere. The NeuroBasal medium (without L-
glutamate) was replaced after the first day and replaced again after 5 days culture. 
 
2.2.2 Subcloning of the target gene into a mammalian expression 
vector 
 The Bcl-xL wildtype gene was amplified from the Bcl-xL/pcDNA3 plasmid. Both 
PCR fragment and pCMV/FLAG3 vector were restricted with EcoR I and Bgl II (Fermentas) 
at 37ºC for 2 hours. The purified fragments were then ligated using T4 DNA ligase 
(Fermentas) (16ºC overnight). After transformation, positive clones were detected by colony 
PCR, with PCR fragments being visualized by agarose gel electrophoresis containing 1% 
ethidium bromide (EB) and compared to DNA molecular weight standards (Fermentas). 
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Table 2.1 
Company Address 
American Type Culture Collection Manassas, VA, USA 
BD Biosciences Mississauga, ON, CANADA 
BDH Inc Toronto, ON, CANADA 
Bio-Rad Hercules, CA, USA 
Cell Signaling Technology, Inc Danvers, MA, USA 
EMD Biosciences Inc San Diego, CA, USAA 
EMD Chemicals Inc Gibbstown, NJ, USAA 
Fermentas Inc Burlington, ON, CANADA 
GIBCO-BRL Gaithersburg, MD, USA 
Hyclone Logan, UT, USA 
ICN Biomedicals Aurora, OH, USA 
Invitrogen Carlsbad, CA, USA 
Pierce Rockford, IL, USA 
Santa Cruz Biotechnology, Inc Santa Cruz, CA, USA 
Sigma-Aldrich St. Louis, MO, USA 
Stratagene La Jolla, CA, USA 
VWR West Chester, PA, USA 
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Table 2.2 
Antibody Dilution Ratio Source Company 
primary antibody  
Phospho-Akt (Ser473) 1:750 Rabbit Cell Signaling  
Phospho-Akt (Thr308) 1:750 Rabbit Cell Signaling  
Akt  1:750 Rabbit Cell Signaling  
Bcl-xL 1:500 Mouse Santa Cruz 
Bcl-xS 1:500 Rabbit Santa Cruz 
Bcl-xL/S 1:1000 Mouse Santa Cruz 
Bax 1:750 Rabbit Santa Cruz 
Bax-NT 1:750 Rabbit Upstate  
Phospho-Bad (Ser136)  1:500 Rabbit Cell Signaling  
Bad 1:400 Rabbit Cell Signaling  
Caspase-3 1:1000 Rabbit Santa Cruz 
Caspase-9 1:500 Rabbit Santa Cruz 
MAP2 1:750 Rabbit Santa Cruz 
PARP 1:750 Rabbit Santa Cruz 
Fodrin  1:1000 Mouse Sigma   
anti-FLAG 1:1000 Mouse Sigma 
VDAC 1:750 Mouse Calbiochem 
Cytochrome c 1:500 Mouse BD Bioscience  
β-actin 1:3000 Mouse Sigma 
secondary antibody 
Goat Anti-Mouse IgG -HRP Conjugate 1:2000  Bio-Rad 
Goat Anti-Rabbit IgG -HRP Conjugate 1:2000  Bio-Rad 
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2.2.3 Transformation of bacterial cultures 
 Transformation is a basic technique that introduces a foreign plasmid into bacteria 
and uses the bacteria’s “machinery” to amplify the plasmid (in order to get large amounts of 
that plasmid). The procedure for transformation is as follows:  
1. Defrost DH5α competent cells (from -70ºC stock) on ice. 
2. Put 1 μl of plasmid cDNA into a 15 ml BD Falcon tube and add 50 μl of 
DH5α competent cells and incubate on ice for 30 min. 
3. Heat shock the competent cell/ plasmid DNA mix at 42ºC (waterbath) for 45 sec. 
4. Put the tube back on ice for 2 min and add 250 μl of SOC medium  
5. Incubate the tube at 37ºC in an incubator/shaker for 1 hour.  
6. Spread bacterial culture on DYT/Amp+ plate; incubate at 37ºC for 16-18 hours. 
7. Pick up colonies (these are ampicillin resistant and, thus, must have been transformed 
with the plasmid) and screen for positive clones by colony PCR.  
 
2.2.4 Polymerase chain reaction (PCR) 
 The following general PCR protocol (total reaction volume 50 µl) was used to test for 
the presence of a cDNA insert in a particular plasmid or for colony screens (using the actual 
bacterial colony), which tests for a cDNA insert following a ligation/transformation 
experiment. Optimal reaction conditions (i.e. total volumes of reactions, primers, 
concentrations of DNA polymerase, incubation temperatures and times, template DNA, as 
well as MgCl2) were optimized for each DNA fragment.  
1. To a sterile thin wall PCR tube on ice, add and mix the following components:  
5 μl 10× PCR buffer (includes MgCl2)  
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5 μl dNTP mixture (Invitrogen, 2 mM)  
1.5 μl Sense primer (20 μM) 
1.5 μl Anti-Sense primer (20 μM) 
1 ng Template plasmid (or a bacterial colony) 
0.5 μl Taq DNA polymerase (MBI Fermentas)  
Autoclaved distilled water, up to 50 μl per reaction 
2. Cap the tube and centrifuge briefly. Put the sample in the PCR thermocycler.  
3. Perform 25-30 cycles of PCR amplification as follows:  
Denature at 94ºC for 30 sec  
Anneal at 52-55ºC for 30 sec  
Extend at 72ºC for 1 min (generally 1 min per kb being amplified). 
4. Incubate the sample at 72ºC for an additional 5 min and maintain the reaction at 4ºC. The 
sample can then be stored at -20ºC.  
5. Visualize the amplification products by agarose gel electrophoresis with ethidium bromide 
and DNA molecular weight standards (MBI Fermentas).  
6. Purification of the amplified DNA products from the agarose gel was performed by 
QIAEX II Gel Extraction Kit (Qiagen), according to the manufacturer’s protocol.  
 
2.2.5 Mutagenesis of specific Serine residues 
 The QuickChange Site-Direct Mutagenesis kit was used to generate the Bcl-
xL(S62A), Bcl-xL(S106A) and Bcl-xL(S228A) serine-to-alanine substitutions (blocks the 
ability to be phosphorylated on these serines).  
 Using Bcl-xL wildtype cDNA as a template, all three pairs of primers (forward and 
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reverse: substituted codons are underlined, see below) for single amino acid mutations were 
designed according to the manufacturer’s specifications.  All primers are designed as follow: 
 
 Bcl-xL(S62A) 
 Forward: 5’-GCA CCT GGC AGA CGC CCC CGC GGT GAA TGG-3’ 
 Reverse: 3’-CGT GGA CCG TCT GCG GGG GCG CCA CTT ACC-5’ 
 
 Bcl-xL(S106A) 
 Forward: 5’-GTA CCG GCG GGC ATT CGC TGA CCT GAC ATC CCA GC-3’ 
 Reverse: 3’-CAT GGC CGC CCG TAA GCG ACT GGA CTG TAG GGT CG-5’ 
 
 Bcl-xL(S228A) 
 Forward: 5’-TTC TGC TGG GCG CAC TCT TCA GTC GG-3’ 
 Reverse: 3’-AAG ACG ACC CGC GTG AGA AGT CAG CC-5 
 
The PCR-based procedure for mutagenesis is as follow: 
1. Add all reagents (except primers, all are from Stratagene) in an autoclaved PCR tube: 
 10×Reaction buffer   5 μl 
 Plasmid cDNA template (50 ng) 2 μl 
 Forward primer (125 ng/μl)  1 μl 
 Reverse primer (125 ng/μl)  1 μl 
 dNTP mix    1 μl 
 ddH2O     40 μl 
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2. Vortex tube and add 1 μl of Pfu Turbo DNA polymerase 2.5 U/μl (Stratagene). 
3. Place the tube into the PCR machine (thermocycler) and amplify the cDNA using the 
following program: 
 First step:          1 cycle: 95ºC for 30sec 
 Second step:   16 cycles: 95ºC for 30sec 
      55ºC for 1min 
      68ºC for 6min 30sec 
 Third step:    4ºC, overnight. 
4. Put the PCR tube back on ice for 2 min. 
5. Add 1 μl of 10 U/μl Dpn I (Stratagene) into PCR tube and mix well to digest the 
methylated template plasmid cDNA. 
6. Incubate at 37ºC for 1 hour. 
7. Defrost XL1-Blue super competent cell (Stratagene) on ice. 
8. Combine 1 μl of PCR-amplified plasmid cDNA with 50 μL of competent cell in a 15 
ml Falcon tube on ice for 30 min. 
9. Heat shock the mixture at 42ºC for 45 sec. 
10. Put the tube back on ice for 2 min and add 500 μl of NYZ+ (10 g NZ amine casein 
hydrolysate, Sigma; 5 g Bacto-Yeast extract, BD Bioscience; 85.5 mM NaCl, 12.5 
mM MgCl2, 12.5 mM MgSO4, EMD Chemicals Inc; 20 mM glucose, BDH; pH 7.5) 
preheated to 42ºC. 
11. Incubate the tube in the incubator/shaker at 37ºC for 1 hour at 250 RPM.  
12. Spread bacterial culture on DYT/Amp+ plate; incubate at 37ºC for 16-18 hours. 
13. On the following day, pick colonies (ampicillin resistant) and screen for the 
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plasmid/cDNA insert using colony PCR.  
 
2.2.6 Mini-prep 
 Mini-prep’ing is a process for amplifying small amounts of plasmid DNA for 
sequencing or colony screens. The mini-prep procedure is as follows: 
a) Bacterial growth and cell harvesting  
1. Transfer a bacterial colony into 5 ml of Terrific Broth medium (TB, 12 g Bacto-
Tryptone, BD Bioscience; 24 g Bacto-Yeast extract, BD Bioscience; 4 ml glycerol, 
MP Biomedicals; 900 ml ddH2O; autoclaved) containing 0.5 ml of 0.17 M 
KH2PO4/0.72 M K2HPO4  (J.T. Baker) and add ampicillin to the solution (final 
concentration: 50 μg/mL).  
2. Incubate overnight at 37ºC, 250 RPM in bacterial shaker. 
3. Take 1.5 ml of culture and centrifuge at 12000g for 30 sec at room temperature. 
4. Store the remainder culture at 4ºC and remove supernatant by aspiration.  
 
b) Lysis by alkali  
1. Add 100 μl of ice-cold Solution I (50 mM Glucose; 10mM EDTA, pH 8.0; 25 mM 
Tris (base), pH 8.0) and resuspend bacteria by vigorous vortexing.  
2. Add 200 μl of Solution II (0.2 N NaOH, 1% sodium dodecyl sulfate (SDS)) and mix 
content gently by inverting tube back and forth 10 times and set tube on ice for 5 min.  
3. Add 150 μl of ice-cold Solution III (5 M potassium acetate solution, pH 4.8) mix 
gently by rapid inverting tube. Set the tube on ice for 5 min. 
4. Centrifuge tube at 12000g for 5 min at 4ºC, transfer supernatant to a new tube. 
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5. Add 450 μl of phenol (Sigma): Chloroform (BDH) and mix well. 
6. Centrifuge tube at 12000g for 2 min and transfer top phase to a new tube. 
7. Precipitate double-strand DNA with 2 volumes of 100% ethanol (EMD Chemicals Inc) 
at room temperature for 2 min. 
8. Centrifuge at 12000g for 10 min at room temperature and remove supernatant. 
9. Wash DNA with ice-cold 70% ethanol and centrifuge at 4ºC (12000g for 10min). 
10. Remove excessive liquid and speed-vacuum for 20 min. 
11. Re-dissolve the pellet in 40 μl of TE pH8.0 (10 mM Tris, 1mM EDTA) containing 
DNAse-free pancreatic RNAse (20 μl/ml). 
12. Incubate at 20ºC for 20 min, can be stored at -20ºC. 
13. Dilute plasmid DNA at 1:80 (stock:H2O), measure DNA concentration by UV-
spectrometry at an absorbance of 260 nm. 
14. (For sequencing, take 5 μl of 4 μM CMV primer (from 100 μM stock) and 5μl of 100 
ng/μl plasmid DNA.)  
 
2.2.7 Maxi-prep 
 Maxi-prep’ing is a large-scale process for amplifying and purifying plasmid cDNA. 
The procedure is similar to mini-prep. 
a) Bacterial growth and cell harvesting  
1. Transfer a bacterial colony into 5 ml of Terrific Broth medium containing 0.5 ml of 
0.17 M KH2PO4/0.72 M K2HPO4  (J.T. Baker) and add ampicillin (final: 50 μg/mL).  
2. Incubate overnight at 37ºC, 250 RPM in bacterial shaker. 
3. Combine 5 ml of bacterial culture with 270 ml TB and 30 ml 0.17 M KH2PO4/ 0.72 M 
 28
K2HPO4 in a 1L conical flask (make sure the culture contains ampicillin). 
4. Incubate the conical flask at 37ºC, 250 RPM in bacterial shaker, growth 16-18 hours. 
5. The next day centrifuge cells at 4ºC, 5000 RPM 15 min, remove supernatant.  
 
b) Lysis of cells  
1. Add 10 ml of solution I resuspend cells  
2. Add 20 ml of solution II mix gently by inverting bottle back and forth 5 times.  
3. Store at room temperature for 5-10 min. 
4. Add 20 ml solution III and mix well, store on ice for 5 min. 
5. Centrifuge for 15 min at 5000g at room temperature. 
6. Filter supernatant through 4 layer of cheesecloth into a new 250 ml centrifuge bottle. 
7. Add 48 ml of isopropanol (EMD Chemicals Inc) and mix well. Then keep at room 
temperature for 1 hour.  
8. Centrifuge for 15 min at 5000g at room temperature. 
9. Remove supernatant and rise with 85% ethanol, air dry and then dissolve pellet in 3 ml 
TE. 
 
c) Plasmid DNA purification   
1. Pour DNA solution (from #9, above) into a 15 ml tube, add 4.8 ml lithium chloride 
(LiCl, J.T. Baker ). 
2. Centrifuge at 9000g for 10 min at room temperature.  
3. Transfer supernatant to a new tube. Add 7.8 ml of isopropanol and centrifuge at 9000g 
for 10 min at room temperature.  
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4. Remove supernatant and rinse pellet with 85% ethanol, air-dry and dissolve pellet in 
500 μl TE with 5 μl of RNAse (10 mg/ml). 
5. Incubate at room temperature for 30 min. 
6. Add 400 μl of 1.6 M NaCl with 13% (w/v) PEG8000, mix and centrifuge at 12000g 
for 2 min at 4ºC.  
7. Remove supernatant and dissolve pellet in 500 μl TE. 
8. Add 500 μl phenol, vortex and centrifuge at 4000g for 5 min at room temperature.  
9. Transfer top phase to a new 1.7 mL Eppendorf tube and extract with phenol again.  
10. Add 500 μl chloroform, vortex, and centrifuge at 4000g for 5 min at room temperature. 
11. Transfer top phase to a new Eppendorf tube, add 5 M NaCl to a final concentration of 
125 mM. 
12. Add two volumes of 400 μl ice-cold ethanol incubate on ice for 5 min. 
13. Centrifuge for 5 min at 12000g, 4ºC. 
14. Remove supernatant and add 200 μl of 85% ethanol, vortex and centrifuge at 12000g 
for 2 min at 4ºC. 
15. Remove supernatant and air dry ethanol. 
16. Dissolve pellet in 300-500 μl nano-H2O. 
17. Adjust plasmid DNA concentration to 1 μg/μl, store at -20ºC.  
 
2.2.8 Transfection of mammalian cultures 
 Transformation of cultured eukaryotic cells with foreign DNA is often called 
transfection. Lipofectamine 2000 (introduces plasmid DNA into cell cultures by lipofection) 
was the transfection reagent used during the current thesis work.  
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 In this study, HEK293A cells and PC12 cells were transiently transfected (allowed 
to express protein for 24 hours or 48 hours). The procedures are as follows: 
1. Use serum-free culture medium to dilute DNA.  
2. Use serum-free culture medium to dilute Lipofectamine2000 regent. 
3. Combined two reagents and incubate at room temperature for 20 min.  
4. Add DNA-Lipofectamine2000 mixture to cell cultures. 
5. Change to fresh culture medium 4 hours post-transfection (this minimizes toxicity 
associated with the transfection reagent).  
6. Incubate cells for 24 or 48 hours at 37ºC with 5% CO2 in cell culture incubator.  
7. After transfection, cells were harvested and washed with 1×PBS, centrifuge at 1000g 
for 5 min at 4ºC.remove supernatant and Lysis with Lysis buffer (1% Triton-X100, 
Sigma; 20mM Tris pH 7.5, ICN Biochemicals; 10% glycerol, MP Biomedicals; 1mM 
EDTA, EMD Chemicals Inc.) containing 100× protease inhibitor cocktail (PIC, 
Sigma) incubated on ice for 30 min, then centrifuge at 16,100g at 4ºC for 20 min. 
8. Determine each cell lysate protein concentration by BCATM protein assay kit(Pierce).  
 
2.2.9 Western blot analysis 
 Western blotting, also known as immunoblotting (because antibodies are used as the 
primary detection tool), is a technique used to detect a specific protein expression in a cell 
extract (or tissue homogenate).  Equal amounts of denatured total protein from cell lysates are 
loaded onto an SDS-polyacrylamide gel. Using electrophoresis, proteins migrate along the 
current and are separated (resolved) according to their molecular weight, i.e. the smaller the 
protein, the faster it will migrate. Proteins are then transferred from the gel to a nitrocellulose 
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or PVDF membrane and the specific protein (now on the membrane) is detected by specific 
primary antibody. This primary antibody is then detected by secondary antibody conjugated 
with horseradish peroxidase. The horseradish peroxidase converts a chemiluminescence 
substrate that can be detected on photographic film. 
  
1. Prepare SDS-PAGE gel (1mm thick), which includes a 12% resolving gel and 4% 
stacking gel, as shown in Table 2.3. 
2. Protein samples are denatured (to their linear structure) by boiling at 100ºC with 4×
Laemmli sample buffer (LB, 8% SDS, 40% glycerol, 10% mercaptoethanol, 0.02% 
bromophenol blue, 0.25 M Tris-HCl pH 6.8 ). 
3. Load protein ladder into one lane and in other lanes load equal amounts of protein, up 
to 40 μl per well. Electrophorese at 110V in 1×running buffer (25 mM Tris-HCl, 
0.1% SDS, 250 mM glycine) until bromophenol blue reaches the bottom of the gel. 
4. Transfer protein from gel to a 0.22 μm nitrocellulose membrane (Bio-Rad) at 25 V for 
90 min in 1×transfer buffer (25 mM Tris-HCl, 0.00375% SDS, 20% methanol, 250 
mM glycine, 4ºC). 
5. Once transferred, remove the membrane to a container and block the non-specific sites 
with 5% milk in 1×TBS buffer (with gentle rocking at room temperature for 1 hour).  
6. Wash membrane with 1×TBS-Tween buffer (25 mM Tris-HCl pH 7.4; 150 mM NaCl; 
0.1% Tween-20, Sigma) for 30 sec and incubate membrane with primary antibody, 
rocking at 4ºC overnight. 
7. Wash the membrane with 1×TBST twice for 10 min per time. 
8. Incubate the membrane with HRP-conjugated secondary antibody for 1 hour in 5% 
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milk with 1×TBST at room temperature.  
9. Wash membrane with 1×TBST three times, 10 min per time. 
10. Incubate membrane for 1 min with ECL Western Blot Detection Reagent (GE 
Healthcare) and expose to film to visualize the bands. 
 
2.2.10 Immunoprecipitation of target protein 
 Immunoprecipitation (IP) is a technique for isolating proteins and for detecting 
protein-protein interactions. This technique can isolate a specific protein from whole cell 
lysate for subsequent analysis by standard Western blotting. The pre-clearing step is to lower 
the non-specific antigen binding with antibody. The procedure is described below: 
a) Sample preparation. 
1. Transfect cells with plasmid DNA and let overexpress 24 or 48 hours. 
2. Treat cells according to the individual experimental design. 
3. Harvest and wash cells once with 1×PBS. 
4. Lyse cells with Lysis Buffer containing 1×PIC (protease inhibitor cocktail, Sigma) on 
ice for 30 min. 
5. Centrifuge cell lysate at 14000g for 20 min and determine protein content. 
 
b) Pre-clearing 
1. Take 100-500 μg of protein in 400 μl of Lysis Buffer containing 1×PIC. 
2. Add 1-5 μg of Mouse IgG (in a ratio of 1:100, antibody:protein) and 30 μl of 
sepharose A+G, rocking at 4ºC for 1 hour. 
3. Centrifuge at 9000g for 10 min, move pre-cleared supernatant to a new tube (350 μl). 
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Table 2.3 
 12% Resolving Gel (10 ml) 4% Stacking Gel (5ml) 
ddH2O 3.34ml 3.00ml 
Buffer A 2.50ml - 
Buffer C - 1.25ml 
Acrylamide  4.00ml 0.67ml 
10% APS 50μl 25μl 
10% SDS 100μl 50μl 
TEMED  10μl 5μl 
 
Buffer A: 1.5 M Tris-HCl, 0.5% SDS, pH 8.8 
Buffer C: 1.5 M Tris-HCl, 0.5% SDS, pH 6.8 
Acrylamide (Bio-Rad) and TEMED (Sigma) were stored at 4ºC. 
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c) Antibody incubation 
1. Add 1-5 μg of antibody (1: 100, antibody: protein), rocking at 4ºC overnight. 
2. Then add 30 μl of sepharose A+G rocking at 4ºC for 2 hours. 
3. Centrifuge at 4ºC at 9000g for 10 min to spin down all Sepharose beads. 
4. [Supernatant can be collected to run on a gel to show immunodepletion has been 
achieved.] 
5. Wash beads with Lysis Buffer three times and centrifuge at 9000g for 5 min each time. 
6. After last wash, get rid of excessive liquid left in the tube and add 30 μl of 2×
Laemmli sample buffer. 
7. Boil at 100ºC for 5 min to denature protein.   
d) Load on the SDS-PAGE (gel). 
 
2.2.11 Immunofluorescence and double-staining   
 Hoechst 33258 (Sigma), DAPI (4, 6-diamidino-2-phenylindole, Invitrogen), MAP2 
(Santa Cruz), FLAG (Sigma) and Phospho-Akt Ser473/ Thr308 (Cell Signaling) were used for 
immunofluorescence staining. Microtubule-associate protein 2 (MAP2) belongs to 
microtubule-associated protein family and stabilizes microtubule growth by crosslinking other 
intermediate filament and microtubules. Hoechst 33258 fluorescently labels DNA and was 
used to examine chromatin condensation. DAPI can bind with double-stranded DNA and 
forms a fluorescent complex that allows the visualization of the nucleus.   
PC12 cells were plated in 8-well chamber slides coated with rat-tail collagen. After the 
appropriate treatment, cell culture medium was removed and cells were fixed with 4% PFA 
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for 1 hour and then stored until needed for staining. 
The staining procedure is as follows: 
1. Wash with 1×PBS 1time for 5 min to get rid of PFA. 
2. Permeabilize cells with 0.25% Triton-X100 (2% BSA) in 1×PBS for 1 hour. 
3. Add anti-MAP2 primary antibody in 1:250 dilution ratio to each well (125 μl/well) in 
a dark humid environment; incubate for 1 hour (overnight, if necessary). 
4. Rinse with 1×PBS 1time for 5 min. 
5. Add secondary antibody Donkey-anti-Rabbit (or anti-Mouse) FITC-conjugate at a  
1:200 dilution to each well (200 μl/well) and incubate at room temperature for 2 hours. 
6. Rinse with 1×PBS for 5 min. 
7. Add Hoechst 33258 (50 μg/ml stock) in a 1:100 dilution ratio or add DAPI (9 mM 
stock) in a 1:3000 dilution, and incubate in the dark for 5-10 min. 
8. Wash with 1×PBS twice for 10 min. 
9. Remove all liquid and air dry for 5 min. 
10. Add a few drop of Prolong Gold anti-fade medium (Invitrogen) and seal well. 
11. Immunodetection was performed on an Olympus FV300 confocal microscope or on an 
Olympus BX-51 fluorescence microscope.  
 
2.2.12 MTT conversion assay 
 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is a 
method to determine mitochondrial function and is often used as a means of determining the 
toxicity of a potential medical reagent (i.e. more toxicity = less mitochondrial function).  
Cells were plated in a 96-well plate and grown overnight. After treatment, culture 
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medium was removed and 50 μl of 0.5 mg/mL MTT (diluted in DMEM medium containing 
1% FBS from 5 mg/mL stock) was added. The cells were left to incubate at 37ºC for 2-4 
hours. After incubation, 100 μl of DMSO was added to dissolve the purple formazan crystals. 
MTT conversion/cell viability was tested by quantify the absorbance of the colored solution 
by Spectra Max plus 384 microplate reader (Molecular Devices) at 570 nm. 
 
2.2.13 Statistics 
Significance (set at P<0.05) was assessed by unpaired t-test or by one-way ANOVA with post 
hoc analyses relying on Bonferroni’s Multiple Comparison Test (GRAPHPAD PRISM v3.01; 
GraphPad Software Inc., San Diego, CA, USA). Data are represented as mean ± SEM. 
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3. Results  
3.1 Specific Serine residues in pro-apoptotic Bcl-xS dictate its 
toxicity. 
 Dr. Zelan Wei, a postdoctoral researcher in our laboratory, originally chose to 
investigate the role(s) of three Serines in the regulation of pro-apoptotic Bcl-xS function. The 
three residues were substituted for Alanines so as to “mimic” dephosphorylation and were 
chosen because: (a) Ser62 is a potential inactivation mutant (homologous to Ser70 in Bcl-2, 
[30, 36]); (b) Ser106 resides within a putative Akt phosphorylation motif (RXXRXXS); and (c) 
Ser165 lies immediately upstream of the hydrophobic tail (homologous to Ser184 in Bax, 
which is known to influence the mitochondrial localization and toxicity of Bax, [89]). This 
same justification applies to the substitution of Ser62, S106 and S228 in Bcl-xL (examined 
later). 
 In collaboration with Dr. Wei, the three Bcl-xS Ser-to-Ala variants were expressed 
in PC12 cells and cytotoxicity was determined using MTT conversion. Of the three mutations, 
only Bcl-xS(S106A) and Bcl-xS(S165A) decreased PC12 cell viability (Fig. 3.1). The 
expression of Bcl-xS variants was difficult to accomplish in PC12 cells (Fig. 3.1, bottom 
panels), yet they were still able to exert cytotoxic effects.  
 The three Bcl-xS Ser-to-Ala variants were also expressed in HEK cells (often used 
for signalling studies because of their capacity for overexpressing proteins). The three variants 
expressed well in HEK cells (Fig. 3.2, bottom panels) and all three decreased HEK cell 
viability (again determined using MTT conversion) (Fig. 3.2). 
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Figure 3.1: Overexpression of Bcl-xS Ser-to-Ala variants affects PC12 cell viability. Bcl-
xS S62A, S106A and S165A variants were overexpressed in PC12 cell cultures (lower panels, 
β-actin was included to demonstrate equal protein loading). Cell viability was determined 24 
hours post-transfection using the MTT conversion assay. Only the S106A and the S165A 
variants decreased PC12 cell viability [F(4,29)=25.06, ***P<0.001].  (Used with permission, ref 
[44]). 
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Figure 3.2: Overexpression of Bcl-xS Ser-to-Ala variants affects HEK cell viability. Bcl-
xS S62A, S106A and S165A variants were overexpressed in HEK cell cultures and cell 
viability (MTT conversion) was determined 24 hours post-transfection. All three variants 
expressed very well (lower panels, β-actin was included to demonstrate equal protein loading) 
and all three variants decreased HEK cell viability [F(4,29)=32.72, ***P<0.001]. (Used with 
permission, ref [44]). 
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For the remainder of these studies, we chose to focus on the Bcl-xS(S106A) variant as the 
working hypothesis is that Ser106 is a novel target for Akt as it resides in a putative Akt 
consensus motif. 
 Bcl-xS(S106A) was overexpressed in PC12 cells as well as in HEK cells for 24 
hours. Cells were then harvested and homogenized. Subcellular fractions (mitochondrial and 
cytosolic) were then collected by differential centrifugation. In PC12 cells, the overexpression 
of Bcl-xS(S106A) resulted in the release of cytochrome c (cyto c) from the mitochondrial to 
the cytosolic fraction (Fig. 3.3, left side). The expression of VDAC was similar in both 
vector-transfected (control) and Bcl-xS(S106A) mitochondrial fractions. Examination of TCL 
revealed that PARP was cleaved to the p85 fragment (this cleavage is known to be a caspase-
3-mediated event, [90]). In HEK cells, the overexpression of Bcl-xS(S106A) resulted in a 
different pattern of events (Fig. 3.3, right side). First, cyto c was not released from the 
mitochondrial fraction. Secondly, the expression of VDAC was significantly diminished in 
the Bcl-xS(S106A) extracts and, finally, PARP was not cleaved to the p85 fragment. 
 So as to determine if the effects of Akt on Bcl-xS function could be being mediated 
directly through the Ser106 residue, co-immunoprecipitation experiments were performed. In 
this case, the Bcl-xS proteins were overexpressed in HEK cells (because they express proteins 
so effectively, Fig. 3.4a) and the FLAG-tag was used to specifically immunoprecipitate the 
Bcl-xS WT or S106A proteins from precleared lysates. The isolated immunoprecipitates were 
then resolved by SDS-PAGE and blots were probed for specific proteins. FLAG-Bcl-
xS(S106A) co-immunoprecipitated with VDAC better did the FLAG-Bcl-xS WT protein (Fig. 
3.4a) suggesting that the S106A protein was localizing preferentially to the mitochondrial 
fraction. In a separate set of experiments it was demonstrated that the FLAG-Bcl-xS WT co-
 41
immunoprecipitated better with the pSer473-Akt protein (an activated form of Akt) than did 
the FLAG-Bcl-xS(S106A) variant (Fig. 3.4b). In support of this observation, similar protein 
extracts were immunoprecipitated with the pSer473-Akt antibody and the SDS-PAGE 
resolved proteins were examined for FLAG. Again, a better co-immunoprecipitation was 
observed in extracts expressing FLAG-Bcl-xS (Fig. 3.4b). These data suggest that disruption 
of Ser106 allows Bcl-xS to localize to the mitochondria, where it interacts with VDAC. This 
coincides with its inability to co-immunoprecipitate with activated Akt, thus supporting the 
hypothesis that Ser106 in Bcl-xS is a target for cytoplasmic Akt. 
 
At this point, I chose to undertake the following experiments with the goal of determining 
whether the homologous Serines in the anti-apoptotic protein Bcl-xL, e.g. Ser62, Ser106 & 
Ser228, contributed to overall protein function and to cell viability/phenotype. 
 
3.2 Subcloning of Bcl-xL WT and substitution mutants. 
 The human Bcl-xL cDNA obtained from the Youle Laboratory was confirmed using 
a BLAST search of the NCBI GenBank database. Bcl-xL wildtype (WT) cDNA was then 
subcloned into pCMV/FLAG3 (Fig. 3.5). The restriction sites used for subcloning were Bgl II 
and EcoR I (see section 2.2.2 for protocol, Fig 3.5 and Fig 3.6). The pCMV/FLAG3-Bcl-xL 
construct (Fig 3.5) was sequenced with the CMV primer (Fig 3.7). pCMV/FLAG3-Bcl-xL 
WT was then used to generate the S62A, S106A and S228A substitutions (Fig. 3.8), based on 
homologous Serine-to-Alanine substitutions we had used to study the effect of Serine 
[de]phosphorylation on the pro-apoptotic homologue Bcl-xS [44]. 
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Figure 3.3: Bcl-xS(S106A) exerts different effects on mitochondrial function in PC12 
and HEK cells. The Bcl-xS(S106A) variant was overexpressed in PC12 cells as well as in 
HEK cells for 24 hours. Cells were then harvested for subcellular fractionation studies. Bcl-xS 
overexpression is shown in total cell lysates (TCL) (β-actin was included to demonstrate 
equal protein loading). PARP expression and cleavage (as an indicator of apoptotic cell death) 
was also examined. Note that PARP is cleaved to the p85 fragment in PC12 cells, but not in 
the HEK cells. Furthermore, in PC12 cells, cytochrome c (cyto c) is released from the 
mitochondria (Mito.) into the cytosol (Cyto.). Levels of VDAC, a mitochondrial protein 
important for transport of proteins, including cyto c, across the mitochondrial membranes is 
unaffected by ectopic Bcl-xS expression in PC12 cells. In contrast, cyto c remains 
mitochondrial in HEK cells and the expression of VDAC is significantly reduced. (Used with 
permission, ref [44]). 
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Figure 3.4: The Bcl-xS(S106A) substitution influences the interaction with VDAC and 
with Akt. FLAG-tagged Bcl-xS WT and Bcl-xS(S106A) (S/A) were overexpressed in HEK 
cells. 24 hours later the cells were harvested and pre-cleared cell lysates were then 
immunoprecipitated with the FLAG antibody. (a) The corresponding SDS-PAGE resolved 
proteins were probed for FLAG and VDAC. FLAG-Bcl-xS(S106A) interacted more with 
VDAC than did the FLAG-Bcl-xS WT. The overexpression of the FLAG-tagged proteins and 
the expression of endogenous VDAC were confirmed in total cell lysates (TCL). (b) In a 
separate experiment, pSer473-Akt was shown to immunoprecipitate with FLAG-Bcl-xS, but 
not the S/A variant, while the complementary experiment shows that FLAG-Bcl-xS WT 
immunoprecipitates better than FLAG-Bcl-xS(S106A) with pSer473-Akt. FLAG 
overexpression and Akt expression were examined in TCL. IgG: light chain of the 
immunoprecipitating antibody, n.s.: non-specific band detected at 50kDa. 
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Figure 3.5: Plasmid map of pCMV/FLAG3-Bcl-xS and pCMV/FLAG3-Bcl-xL. The 
pCMV/FLAG3 plasmid is about 5700 basepair (bp). The Bcl-xS (509 bp) and Bcl-xL (721 bp) 
cDNA are inserted using the BglII and EcoRI restriction sites. “Amp” indicates ampicillin 
resistance and is used as a selection marker for positively transformed bacteria. Neomycin is 
used for eukaryote screening (not used in the current thesis work). 
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Figure 3.6: Confirmation of the Bcl-xL cDNA insert in pCMV/FLAG3 using restriction 
analysis. (left) The Bcl-xL WT cDNA was subcloned into the BglII and EcoRI restriction 
sites in pCMV/FLAG. The nucleotide sequence GAATTC (indicated in yellow) is the 
palindromic sequence recognized by EcoRI. (right) The pCMV/FLAG3-Bcl-xL plasmid was 
restricted with either BglII or EcoRI, or with both enzymes, and the reaction was then 
electrophoresed on agarose gel and visualized using ethidium bromide. The single restrictions 
simply linearized the plasmid (i.e. it migrates as a more distinct band at approximately 6.4 
kbp. In contrast, the double-digested plasmid (EcoRI/BglII) releases a 721 bp fragment and an 
approximate 6 kbp fragment (empty vector).  
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(Previous page) 
 
Figure 3.7: The chromatogram covering the Bcl-xL WT cDNA sequence. pCMV/FLAG3-
Bcl-xL was sequenced using the CMV primer (this anneals with the “CMV promoter” of the 
pCMV/FLAG3 vector (see Fig. 3.5). The three FLAG epitope coding sequences are indicated 
(underlined in black) and are found upstream, and in-frame, with the human Bcl-xL cDNA. 
The start of Bcl-xL cDNA is indicated by the “start” arrow. Note that there is no start “ATG” 
codon for the Bcl-xL cDNA as it does not require one; it uses the start “ATG” (red box) and 
the Kozak consensus sequence (red, underlined) immediately upstream of the first FLAG 
epitope sequence. The end of the Bcl-xL cDNA is indicated by the “TGA” stop codon (green 
box) and the “end” arrow. The wildtype codons corresponding to Ser62, Ser106 and Ser228 
are indicated (black boxes) and the codons used for substituting the Serines for Alanines (Ala) 
are shown immediately below each Serine.  
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Figure 3.8: Sequencing confirms the Bcl-xL S62A, S106A and S228A mutations. The 
codon substitution corresponding to the individual Bcl-xL serine-to-alanine (Ser/Ala) 
mutations in pCMV/FLAG3-Bcl-xL are underlined and labeled “Ala” (shown on the right) 
and compared to the corresponding wildtype codons (underlined and labeled “Ser”, shown on 
the left side). 
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3.3 Specific Serine residues in anti-apoptotic Bcl-xL dictate its 
function. 
  FLAG-Bcl-xL WT or the three Ser-to-Ala variants were individually expressed 
in PC12 cells for 48 hours and confirmed by Western blot analysis (Fig. 3.9). The cleavage of 
the initiator caspase-9 to the active 17 kDa fragment was observed in corresponding cell 
lysates as was the cleavage of PARP to the p85 fragment (Fig. 3.9). Note that cleavage of the 
initiator caspase-9 was used to demonstrate a caspase-dependent event in these [PC12] cells 
(in contrast to the executioner caspase-3 used for studies based on Staurosporine-mediated 
effects in primary cell cultures, see Fig. 3.10, below) as caspase-3 is very difficult to detect 
(with any reliability) in PC12 cells. 
 
3.4 Staurosporine-induced toxicity is Akt- and caspase-dependent 
in primary neuronal cultures. 
 Staurosporine, a potent kinase inhibitor, induced primary neuronal cell death in a 
concentration-dependent manner (Fig. 3.10a). Staurosporine did not affect the expression of 
Bcl-xL, but it did inhibit Akt phosphorylation [as evidenced by decreased phosphorylation on 
both Thr308 and Ser473, while Total-Akt remained the same] (Fig. 3.10a). This coincided 
with the appearance of indicators of apoptosis, including the 17 kDa active fragment of the 
executor caspase-3 and cleavage of the caspase-3 targets, i.e. PARP (Poly-ADP ribosome 
polymerase) and Fodrin (a membrane-associated cytoskeletal protein) (Fig. 3.10b). This 
suggests that staurosporine-induced primary neuronal death is an Akt- and caspase-dependent 
event.  
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Figure 3.9: Dephosphorylation of selected serine residues of anti-apoptotic Bcl-xL 
reveals a cytotoxic profile. PC12 cells were transfected with FLAG-Bcl-xL (wildtype and 
the three Serine-to-Alanine substitution variants, S62A, S106A & S228A) for 48 hours. The 
overexpression of FLAG-Bcl-xL(S62A) and FLAG-Bcl-xL(S106A) promote the cleavage of 
the effector caspase-9 (to the p17 (17 kDa) fragment) and the concurrent cleavage of the 
downstream target, PARP (to the p110 and p85 fragments).  
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Figure 3.10: Staurosporine-induced primary cell toxicity is Akt- and caspase-dependent. 
(a) Primary cortical cultures were treated with different concentrations of staurosporine for 24 
h. Cytotoxicity was demonstrated using the MTT conversion assay. (b) Staurosporine did not 
affect Bcl-xL expression, but it did induce the loss of Akt phosphorylation on both Thr308 
and Ser473. It also induced the cleavage of caspase-3 to the active 17 kDa fragment and this 
coincided with the cleavage of the caspase-3 targets Fodrin (to the 120 kDa fragment) and 
PARP (to the 85 kDa fragment).  
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3.5 Staurosporine-induced toxicity in PC12 cells presents with 
indicators of apoptosis.  
 Staurosporine (ST) exerted the same effects in PC12 cells as seen with primary 
neuronal cultures. For example, it inhibited Akt phosphorylation on both Thr308 and Ser473 
in a concentration manner (Fig 3.11a) and induced Hoechst-visualized nuclear condensation 
(a marker of apoptosis) (Fig 3.11b). 
Based on the findings using manipulations of the Bcl-xS protein and as the working 
hypothesis is that Ser106 resides in a putative Akt consensus motif, I chose to focus the 
following experiments on the Bcl-xL(S106A) variant. 
MTT conversion was used to determine how Bcl-xL wt and S106A (24 h expression) 
affected PC12 cell function during treatment with the potent apoptosis inducer ST (1 μM; 24 
h). ST had a significant effect on MTT conversion, but this was not affected by 
overexpression of either of the proteins (Fig. 3.12). Furthermore, Bcl-xL(S106A) tended to 
decrease MTT conversion, although this was not statistically significant. The decrease in 
MTT conversion in these cultures, however, meant that the effect of ST in corresponding 
cultures was no longer significant. 
 To determine potential interactors with Bcl-xL during ST treatment, PC12 cells 
overexpressing FLAG-tagged Bcl-xL wildtype and S106A (for 24 h) were treated with 1 μM 
ST for an additional 24 hour. Protein extracts were immunoprecipitated with the anti-FLAG 
antibody and then SDS-PAGE resolved-proteins were examined for FLAG and for Bax (a 
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Figure 3.11: Staurosporine-induced PC12 cell apoptosis. (a) Akt phosphorylation on 
Thr308 and Ser473 in PC12 cell lysates is diminished modestly with increasing 
concentrations of staurosporin. β-Actin was included to demonstrate equal protein loading. (b) 
PC12 cell nuclear condensation (the nucleus appears broken into small clusters; arrows) in 
cultures treated with 5 μM staurosporine was observed using Hoechst staining.  
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Figure 3.12: Overexpression of Bcl-xL WT and S106A proteins does not alter the 
staurosporine-induced loss of MTT conversion in PC12 cells. PC12 cells were transfected 
with Bcl-xL wildtype or S106A. 24 hours later the cells were treated with 5 μM of 
staurosporine (ST) for an additional 24 hours.  Bcl-xL wildtype did not significantly affect the 
ST-induced decrease in MTT conversion. While the S106A variant tended to decrease MTT 
conversion, this was not significant. However, the effect of ST in Bcl-xL(S106A)-expressing 
cultures was also no longer significant. *: P<0.05; ***: P<0.001; n.s.: not significant; versus 
corresponding vehicle (veh)-treated groups 
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Figure 3.13: Bcl-xL(WT & S106A) interacts with pro-apoptotic Bax in staurosporine-
treated PC12 cells. Staurosporine treatment diminishes total Akt expression as well as the 
expression of Bax (as it also does in primary culture, see Fig. 3.10). This is rescued by 
overexpression of Bcl-xL wildtype but not by the S106A mutant, although both Bcl-xL 
wildtype and S106A mutant associate with Bax in ST-treated PC12 cultures.  
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known interactor of Bcl-xL [91]). Both FLAG-Bcl-xL wildtype and S106A co-
immunoprecipitated better with Bax upon treatment with ST. Interestingly, treatment with ST 
diminished both Akt and Bax expression (as had already been observed in primary culture, 
see Fig. 3.10). This was rescued by overexpression of Bcl-xL wildtype but not by the S106A 
mutant. Furthermore, Bcl-xL wildtype protected Akt expression (as well as the 
phosphorylation status of both Ser473 and Thr308) in the presence of ST. β-Actin expression 
revealed equal protein loading in all lanes (Fig. 3.13).  
 A co-immunoprecipitation experiment was performed to determine how inhibition 
of the PI3K/Akt pathway would affect the interaction between [FLAG] Bcl-xL and Bax. Bcl-
xL WT and S106A were overexpressed in PC12 cells for 24 hours and treated for a further 24 
h with 1 μM staurosporine in the absence or presence of 25 μM LY249002 (LY: a PI3K/Akt 
inhibitor). 48 hours post-transfection the cells were harvested and pre-cleared cell lysates 
were then immunoprecipitated for FLAG and for Akt. The SDS-PAGE resolved proteins 
revealed that FLAG-Bcl-xL(S106A) co-immunoprecipitated better with Akt than did the 
FLAG-Bcl-WT (Fig. 3.14). This interaction was further enhanced by treatment with LY, but 
was equally as strong for the WT and S106A variants. This same trend was observed for the 
interaction between Bcl-xL (WT and S106A) and Bax (Fig. 3.14). Akt was not 
dephosphorylated following treatment with LY. Although this is not what is expected of a 
PI3K/Akt inhibitor, it was not surprising as our laboratory had already noticed that LY 
inhibits PI3K/Akt quite readily in naïve cells, but that it is not as effective, and can actually 
activate Akt, in transfected cells [92]. The effect of LY was confirmed, however, by the loss 
of Akt-Ser473 phosphorylation in Bcl-xL(S106A)-expressing cells as well as by the increase 
in immunodetection of the caspase-3 (17kDa) cleavage product in the vector- and Bcl-xL 
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wildtype-transfected cells (Fig. 3.14). While the effect of the PI3K inhibitor, LY, in these 
cells was unexpected, these data suggest that substitution within the putative Akt consensus 
sequence does not hinder the interaction between Bcl-xL and Akt, but that the interaction 
between Bcl-xL and Akt could affect signalling events downstream of Akt. 
 Since Bcl-xL may be influenced by Akt, immunofluorescence staining was used to 
examine PC12 cells overexpressing Bcl-xL and treated with 1μM of staurosporine (ST) for 24 
hours.  The nuclei were stained with DAPI (Blue) and the overexpression of Bcl-xL was 
visualized using anti-FLAG antibody (green). This demonstrates that staurosporine induces 
PC12 cell neurite outgrowth (shown by green fluorescence) and that this effect is potentiated 
by overexpression of Bcl-xL(S106A) (Fig. 3.15). Different species of the differentiation-
associated MAP-2 protein (microtubule-associated protein-2; [93]) were increased in PC12 
cultures overexpressing Bcl-xL(S106A) and treated with ST (Fig. 3.16), thus corroborating 
the cellular differentiation observed in Fig. 3.15. 
 Finally, I chose to examine the potential for interaction of Bcl-xL(S106A) with 
VDAC, a component of the mitochondrial membrane pore complex and a known target for 
Bcl-xL in certain contexts [94]. The FLAG-tagged Bcl-xL wildtype and S106A variant were 
immunoprecipitated from precleared lysates. The FLAG-Bcl-xL WT and S106A proteins do 
not co-immunoprecipitate with VDAC (levels of VDAC remains the same level in total cell 
lysate) (Fig.3.17). This demonstrates that Bcl-xL(S106A) exerts its effects via a mechanism 
that is distinct from the mechanism of action of its pro-apoptotic analogue Bcl-xS(S106A). 
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Figure 3.14: Mutation of Bcl-xL at Ser106 (a potential Akt target) induces more of an 
interaction with Akt in staurosporine-treated PC12 cells. Bcl-xL WT and mutation were 
overexpressed in PC12 cells for 48 hours, and co-treated with 1 μM staurosporine and 20 μM 
LY (PI3K inhibitor). The FLAG-Bcl-xL(S106A) variant co-immunoprecipitated better with 
the total-Akt protein than did the FLAG-Bcl-WT protein. IgG: heavy chain of the 
immunoprecipitating antibody. 
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___________________________________________________________________________ 
Figure 3.15:  (next page) Bcl-xL(S106A) promotes ST-induced differentiation of PC12 
cells. PC12 cells expressing the GFP-Bcl-xL(S106A) variant (seen here in green) were treated 
with vehicle (veh) or staurosporine (ST) for 24 hours. Neurite outgrowth was used as a ‘read-
out’ of differentiation.  Nuclei were stained with DAPI (Blue). The intensity of the two 
images at the bottom was purposefully increased so as to visualize the very fine neurites in 
these cultures. 
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Figure 3.16: Staurosporine induces MAP-2 cleavage in Bcl-xL(S106A)-expressing 
PC12 cells. Bcl-xL WT and mutation were overexpressed in PC12 cells for 48 hours, and 
treated with 1μM staurosporine. The mutation of Bcl-xL in Ser106 residue has showed MAP-
2 (neuronal specific protein) expression. H.M.W: high molecular weight (~250 kDa); 
mid.M.W:  mid molecular weight (~65 kDa).   
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Figure 3.17: Neither Bcl-xL wildtype nor Bcl-xL(S106A) interacts with VDAC in PC12 
cells. FLAG-tagged Bcl-xL wildtype (WT) and Bcl-xS(S106A) were overexpressed in PC12 
cells. 24 hours post-transfection the cells were harvested and pre-cleared cell lysates were 
then immunoprecipitated with the FLAG antibody. Neither FLAG-Bcl-xL WT and FLAG-
Bcl-xL(S106A) co-immunoprecipitated with VDAC. The overexpression of the FLAG-tagged 
proteins and the expression of endogenous VDAC were confirmed in total cell lysates (TCL). 
IgG: light chain of the immunoprecipitating antibody. 
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4. Discussion 
 The PI3K/Akt pathway exerts some of its effects on cell function via phosphorylation 
of effectors such as the Bcl-2 family of proteins. For example, Bcl-2-Thr56 can be 
phosphorylated during mitosis by CDK [32] and JNK [30]. While this might disable its anti-
apoptotic function [30, 95], it would appear that multisite phosphorylation of Bcl-2 could 
stabilize and promote its anti-apoptotic function [33]. Multisite phosphorylation is also known 
to contribute to the function of Bad; Indeed, the phosphorylation of Bad-Ser112 by ERK and 
Ser136 by Akt [96, 97], on Ser155 (by PKA, but only if Ser136 is phosphorylated: [98]) and 
on Ser170 [42] all contribute to the tight control of this highly effective pro-apoptotic protein. 
Akt-mediated phosphorylation of Bax-Ser184 clearly impedes its translocation from the 
cytoplasm to mitochondrial targets [38]. JNK phosphorylates Bcl-XL within its activation 
loop on Ser62 [36] and possibly on threonine residues [37]. Such phosphorylation, 
particularly on Ser62, is known to contribute to the pro-apoptotic role for Bcl-xL as a 
consequence of diminished capacity to bind and disable pro-apoptotic Bax [99]. The 
phosphoregulation of pro-apoptotic Bcl-xS was, until recently, unclear, but now seems to also 
be regulated by multisite phosphorylation. 
Part of this thesis work contributed to a recent publication [44] that was an extension of 
previous work from our laboratory. In it we had demonstrated that the antipsychotic 
haloperidol could induce Bcl-xS gene and protein expression, and that Bcl-xS could 
translocate to the mitochondria and facilitate cytochrome c release to the cytoplasm [87]. The 
mechanism that triggered the translocation of Bcl-xS was unclear, although a second study 
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clearly implicated a loss of Akt function as a major factor in haloperidol-mediated 
cytotoxicity [67]. With this in mind, our laboratory chose to examine the possibility that Bcl-
xS was a candidate for phosphoregulation. My contribution was the demonstration that Bcl-xS 
proteins that bore directed S/A substitutions were toxic to PC12 cells. In particular, the 
toxicity of the S106A substitution within a putative Akt consensus motif contributed to 
cytochrome c release from the mitochondria and to a caspase-dependent loss of viability in 
these cells. The cytochrome c release was most probably a reflection of the increased ability 
of the Bcl-xS(S106A) protein to co-immunoprecipitate with the channel forming voltage-
dependent anion channel (VDAC), a known factor in mitochondrial effects and cytochrome c 
release in other systems [94, 100, 101]. In support of the S106 residue being a novel target for 
Akt, it was observed that wildtype Bcl-xS co-immunoprecipitated with Akt, but that the 
S106A variant did not. 
I observed that Bcl-xS(S106A)-induced cytotoxicity also relied on a mitochondrial event 
in HEK293A cells, but that there was no corresponding release of cytochrome c. Expression 
of Bcl-xS(S106) did, however, reduce the expression of the VDAC. While the loss of VDAC 
could explain the lack of any cytochrome c translocation to the cytoplasm, this did not explain 
why it was cytotoxic in these cells. It is possible, however, that the disruption of the VDAC-
pore complex would effectively disrupt ATP flux and any ATP-dependent mechanisms, 
ultimately affecting cell function [102]. This is supported indirectly by the conspicuous 
absence in these cells of [caspase-dependent] PARP cleavage (an ATP-sensitive process in 
HEK cells; [103]). Others had previously observed that the mitochondria of Bcl-XS-
expressing [non-neuronal] 3T3 fibroblasts were also almost transparent, indicating a lack of 
membrane content, and that this coincided with the cytosolic depletion of cytochrome c and 
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with caspase-independent death [104, 105]. 
At this point, I decided to investigate whether the anti-apoptotic Bcl-xL homologue 
was affected by phosphorylation on the same residues as we had already examined in the Bcl-
xS studies, namely Bcl-xL Ser62, Ser106 and Ser228 (homologous to Ser165 in Bcl-xS, see 
Fig. 1.3). Although all three substitution variants expressed well in PC12 cells, only the S62A 
and the S106A variants induced the cleavage of caspase-9 and PARP, thus indicating an 
apoptotic phenotype. I again chose to focus on the S106A variant so as to compare and 
contrast the effects of an S106A substitution in both Bcl-xS and Bcl-xL. I also chose to use 
staurosporine, as it is a potent phospholipid/Ca2+-dependent kinase inhibitor [73, 74] that 
induces caspase-dependent apoptotic cell death in neural stem cells [75] and osteoblasts [76],  
apparently by inhibiting Akt [77]. While I could have used haloperidol in these studies, I 
preferred to use staurosporine as it is used regularly in the published literature to study 
cytotoxicity in vitro [78-81], cell cycle arrest at G1/S phase [82], and also to study apoptosis 
and neurite outgrowth (a indicator of differentiation) in [pre]neuronal cells [83, 84, 106]. 
Treatment of PC12 cells with staurosporine decreased MTT conversion (an indicator of cell 
number/viability). The overexpression of Bcl-xL(S106A) tended to decrease MTT conversion 
on its own. While this effect was not significant, it did mitigate the ‘significance’ of the effect 
of staurosporine on MTT conversion. This, in combination with the observation that the effect 
of staurosporine alone or in combination with expressed Bcl-xL(S106A) affected the 
phosphorylation and expression of Akt, in addition to the fact that Bcl-xL(S106A) co-
immunoprecipitated very well with pro-apoptotic Bax indicated two things. First, the effect of 
staurosporine could be mediated by a dephosphorylated Bcl-xL species and second, the 
combination of staurosporine and Bcl-xL(S106A) was not promoting an apoptotic phenotype 
 66
(because the interaction between Bcl-xL and Bax is a known protective mechanism: see ref. 
[35]). The latter conclusion was further confirmed by the inability of Bcl-xL(S106A) to 
interact with VDAC. The fact that Bcl-xL interacted with Akt (in staurosporine-treated PC12 
cultures) and even more so with Bcl-xL(S106A), and that inhibition of PI3K with LY249002 
enhanced the interaction between Bcl-xL wildtype, but not that of Bcl-xL(S106A), clearly 
implicated the PI3K/Akt cascade in the effects of Bcl-xL(S106A). Interestingly, the lack of a 
profound effect of LY249002 in transfected cells is not unexpected [92], but the loss of Akt 
phosphorylation in the Bcl-xL(S106A) cultures treated with staurosporine could be promoting 
a differentiating phenotype (see ref. [92]). In support of this, corresponding PC12 cell cultures 
clearly revealed morphological changes characteristic of differentiation. This was supported 
by the appearance of MAP-2 cleavage products that are usually associated with such 
differentiation phenotypes [93].  
In summary, the Ser106 residues in both Bcl-xS and Bcl-xL appear to be targets for the 
Akt kinase. Interestingly, overexpression of the phospho-defective S106A variant can be 
either pro-apoptotic (in the case of Bcl-xS(S106A)) or pro-differentiation (in the case of Bcl-
xL(S106A)). My work clearly demonstrates the contribution of Bcl-xS to the cytotoxicity 
profile of the antipsychotic haloperidol and also links the phosphoregulation of Bcl-xL to the 
effect of the kinase inhibitor staurosporine. Future studies would require an examination of 
the role of Bcl-xS/xL in the effector profile of both of these drugs given that haloperidol is 
also implicated in differentiation and that staurosporine is also involved in aspects of 
apoptosis. This is perhaps not surprising as differentiation requires a cell cycle arrest that, if 
held too long, leads to an apoptotic phenotype. Finally, determining the role of Bcl-xS/xL 
phosphoregulation in the profile of cancer therapeutics [44, 87, 107] would be interesting. 
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